Initial clinical outcomes of intracoronary infusion of autologous progenitor cells in patients with acute myocardial infarction

Seyed Mohammad Hashemi Jazi(1), Mohammad Hossein Nasr Esfahani(2), Mehrfarin Fesharaki(3), Fariba Moulavi(4), Mojgan Gharipour(5)

Abstract

BACKGROUND: Myocardial infarction (MI) is an irreversible cardiomyocytes injury which begins after 15-20 minutes of coronary artery occlusion. The extent of infarction is modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Although angioplasty and thrombolytic agents can relieve the cause of the infarction, the time from the occlusion onset to reperfusion determines the degree of irreversible myocardial injury. Experimental studies suggested that stem cells and progenitor cells derived from bone marrow can be used in the repair of cardiac tissue after acute MI. This study was designed to investigate the feasibility, safety and initial clinical outcome of intracoronary infusion of autologous progenitor cells in patients with acute MI.

METHODS: Patients with a history of anterior MI and a left ventricular ejection fraction (LVEF) less than 35 % who were candidates for coronary angioplasty were randomly allocated in a 1:1 ratio to either control or bone marrow cell groups (each including 16 patients). Thallium scan and 17-segment echocardiography analysis for regional wall motion abnormality were performed before and 1 and 6 months after intracoronary infusion of bone marrow cells. The same tests were also conducted for the control group at identical time intervals. Quantitative variables were compared by independent t-test and paired t-test. Statistical significance was assumed at a value of P < 0.05.

RESULTS: LVEF in the case and control groups increased to 39.37 ± 2.47% and 31.00 ± 1.87%, respectively (P = 0.069 and 0.1, respectively). Wall motion abnormality index (WMAI) decreased insignificantly in both groups. Perfusion defect scores (PDSs) decreased significantly in the case group.

CONCLUSION: In this study, autologous mesenchymal stem cell transplantation byintracoronary catheter during angioplasty in patients with a history of severe LV dysfunction caused mild increases in LVEF.

Keywords: Myocardial Infarction Left Ventricular Failure, Stem Cell.

ARYA Atherosclerosis Journal 2012, 7(4): 162-167

Date of submission: 28 Sep 2011, Date of acceptance: 13 Dec 2011

Introduction

Myocardial infarction (MI) is, by nature, an irreversible myocardial injury. Regional systolic function and regional metabolism decrease within a few heart beats of a sudden decrease in myocardial perfusion. In some patients, impaired diastolic relaxation may precede global systolic abnormalities. Irreversible cardiomyocytes injury begins after 15-20 minutes of coronary artery occlusion. The subendocardial myocardium has high metabolic needs and thus is most vulnerable to ischemia. The extent of the infarction depends on the duration and severity of the perfusion defect. However, the extent of infarction is also modulated by a number of factors including collateral blood supplies, medications, and ischemic preconditioning. Beyond contraction and fibrosis of myocardial scar, progressive ventricular remodeling of non-ischemic myocardium can further reduce cardiac function in the weeks to month after the initial event.
Many of the therapies available to clinicians today can significantly improve the prognosis of patients with acute myocardial infarction. Although angioplasty and thrombolytic agents can relieve the cause of the infarction, the time from onset of occlusion to reperfusion determines the degree of irreversible myocardial injury. No clinical medication or procedure has been proved efficient in replacing myocardial scar with functioning contractile tissue. Therefore, stem cells and progenitor cells derived from bone marrow have been proposed to be used in repairing the cardiac tissue after acute myocardial infarction. Experimental studies suggested that bone marrow-derived or blood-derived progenitor cells may contribute to the regeneration of infarcted myocardium and enhance neovascularization of ischemic myocardium. Furthermore, studies have revealed that the subset of cells in the bone marrow can be mobilized to peripheral circulation and can localize the endothelial flow surface of the vascular prosthesis. In addition, intracoronary infusion or intramyocardial injection of adult progenitor cells in animal models resulted in sustained improvement of cardiac function after experimentally induced myocardial infarction. Therefore, this study aimed to investigate the feasibility, safety and initial clinical outcome of intracoronary infusion of autologous progenitor cells in patients with acute MI.

**Materials and Methods**

This study was done from June 2002 – January 2004. Patients were eligible if they had a history of anterior MI, by history, electrocardiography, and cardiac enzymes during the past month. All included patients had a left ventricular ejection fraction (LVEF) less than 35% and were candidates for coronary angioplasty. Patients with multivessel coronary artery disease, pulmonary edema, radiogenic shock, advanced renal or hepatic dysfunction, or cancer were excluded. Informed consents were obtained from all patients. Moreover, the study protocol was approved by the local Ethics Committee of Isfahan University of Medical Sciences. Although, 55 patients were initially admitted, only 20 had the inclusion criteria and were candidates for coronary angioplasty. Patients with multivessel coronary artery disease, pulmonary edema, radiogenic shock, advanced renal or hepatic dysfunction, or cancer were excluded. Informed consents were obtained from all patients. Moreover, the study protocol was approved by the local Ethics Committee of Isfahan University of Medical Sciences. Although, 55 patients were initially admitted, only 20 had the inclusion criteria and were randomly allocated in a 1:1 ratio to the either control or case (bone marrow cell) groups. After angioplasty and stent deployment, coronary artery was occluded at the origin of the stent and progenitor cells were injected in 3 steps of 3 minutes duration.

**Harvest and transfer of bone marrow cells**

Bone marrow aspirates were obtained under local anesthesia with a standard Jamshidi needle with heparin (50 U/ml) from posterior iliac crests. Bone marrow-derived mononuclear cells (BMCs) were isolated by layering on a Ficoll-Paque gradient. Cell populations included hematopoietic progenitor cells. A hemocytometer was used to estimate the number of nucleated cells in the final preparation of bone marrow cells. Nucleated cell viability was assessed by trypan blue exclusion. Nucleated cells were cultured in an M199 medium, 10% human serum supplemented with 50 ng/ml vascular endothelial growth factor (VEGF), 1 ng/ml basic fibroblast growth factor (bFGF), and 2 ng/ml insulin-like growth factor-1 (IGF-1). The cells were incubated overnight at 37°C in a fully humidified atmosphere with 5% CO₂. Then, cells were washed twice, resuspended in 5 ml human serum and infused into the infarct artery during the angioplasty procedure.

Selective coronary and left ventricular (LV) angiography were carried out according to the standard Seldinger method.

**SPECT thallium scan**

Perfusion defects in 17 segments were assessed by scintigraphy using bull's-eye analysis for both the control and case groups before and six months after the procedure.

**Echocardiography**

The 17-segment model for regional wall motion analysis of LV and LVEF was evaluated before, and 1 and 6 months after intracoronary infusion of bone marrow cells. It was also assessed at the same intervals in the control group.

**Statistical analysis**

Data was expressed as mean ± SEM. Initially, the Kolmogorov-Smirnov test was used to determine the normality. Then categorical variables were compared with the use of one way ANOVA. Statistical significance was assumed at a level of P < 0.05. All statistical analyses were performed using SPSS.

**Results**

On average, 128 ± 5.5ml of bone marrow was aspirated from the posterior iliac crest during the local anesthesia. The average preparation of bone marrow cells contained 24.6 × 10⁸ ± 8.4 × 10⁸ nucleated cells with approximately 99% viability.

Baseline characteristics of the patients are shown in table 1. Treatment with aspirin, Captopril, and Lovastatin was initiated during the hospitalization for MI and continued until the follow-up examination at the 6th month. Ticlopidine was used by both groups for 1 month after angioplasty. There were no deaths or reoccurrence of MI. None of the patients had any malignant arrhythmia during the follow-up period, had any clinical findings suggestive of exacerbation of heart failure or re-stenosis of the stent lesion in the infarct.
artery. In addition, there were no increases in white blood cell (WBC) counts in any of the patients 24 hours after the intracoronary transfer of bone marrow cells. 

LVEF was 33.37 ± 2.8% and 29.00 ± 1.87% respectively in the bone marrow treated and control groups before treatment. There was no significant difference between these values. In the bone marrow group, the LVEF increased to 39.37 ± 2.47% in 6 months which was significantly different (P = 0.069) from the values before treatment. An insignificant increase was also observed in the level of LVEF (31.00 ± 1.87%) in the control group. Although the difference in the LVEF values between the bone marrow and control groups before treatment was not significant, it was significant after 6 months.

The values of wall motion abnormality index (WMAI) in the bone marrow treated and control groups (36.88 ± 2.5% and 35.60 ± 4.8%, respectively) were not significantly different before treatment. The WMAI decreased to 36.00 ± 3.86% and 34.40 ± 4.46% respectively in the bone marrow treated and control groups after 6 months. The differences were not significant in either group. The difference between WMAI in the bone marrow and control groups after treatment was not significant.

Perfusion defect scores (PDSs) were 31.00 ± 3.04 and 35.00 ± 4.09 in the bone marrow treated and control groups before treatment. There was no significant difference between these values. Although after 6 months, the PDSs decreased to 21.88 ± 4.27 and 31.00 ± 4.50 in the bone marrow treated and control groups, respectively, the difference was only significant in the first group (P ≤ 0.05). The difference in the PDSs between the bone marrow and control groups was significant after 6 months (P ≤ 0.05).

Functional class index (FCI) was assessed by a cardiologist according to New York Heart Association classification. FCI was 2.38 ± 0.26 and 2.2 ± 0.20 in the bone marrow treated and control groups before treatment. There was a significant difference between these values. In the bone marrow group, the FCI decreased to 1.13 ± 0.12 after 6 months which was significantly different from the value before treatment. Similarly, the FCI significantly decreased to 1.06 ± 0.24 in the control group. The difference in FCI between the bone marrow and control groups was significant after 6 months. The results are shown in table 2.

### Table 1. Basic characteristics of the two studied groups

|                          | Control Group (n = 16) | Case Group (n = 16) |
|--------------------------|------------------------|---------------------|
| Age (yrs)                | 45.20 ± 3.16           | 48 ± 2.48           |
| Sex (Male%)              | 90%                    | 66%                 |
| Diabetes mellitus        | 25%                    | 33%                 |
| Hyperlipidemia           | 40%                    | 33%                 |
| Hypertension             | 0%                     | 33%                 |
| Current cigarette use    | 40%                    | 32%                 |

### Table 2. Evaluated parameters in the two studied groups

|                          | Control group | Bone marrow cell treated group | P     | Control group | Bone marrow cell treated group | P     |
|--------------------------|---------------|--------------------------------|-------|---------------|--------------------------------|-------|
|                          | Before        | After 6 months                 |       | Before        | After 6 months                 |       |
| LVEF* %                  | 29±1.87       | 31±1.87                        | ≤ 0.05| 33.37±2.80    | 39.37±2.47                     | 0.069 |
| FCI** (NYHA)             | 2.20 ± 0.20   | 1.06±0.24                      | 0.005 | 2.38±0.26     | 1.13±0.12                      | < 0.001|
| WMAI***%                 | 35.60 ± 4.8   | 34.4 ± 4.46                    | 0.388 | 36.88 ± 2.50  | 36.00±3.86                     | 0.757 |
| Defect score             | 35.00±4.09    | 31.00±4.50                     | 0.052 | 31.00±3.04    | 21.88±4.27                     | 0.065 |

* Left ventricular ejection fraction  
** Functional class index  
*** Wall motion abnormality index
Discussion

Rapid reperfusion of the infarct-related coronary artery is of great importance in salvaging ischemic myocardium and limiting the infarct size in patients with acute MI. When done expeditiously and expertly, percutaneous transluminal coronary angioplasty with stent implantation is the method of choice to re-establish coronary flow.\textsuperscript{16} Unfortunately, myocardial necrosis starts rapidly after coronary occlusion, usually before reperfusion can be achieved.\textsuperscript{17}

The loss of viable myocardium initiates a process of adverse LV remodeling, leading to chamber dilatation and contractile dysfunction in many patients.\textsuperscript{18} In this context, much interest has been paid to experimental studies showing that cardiac transfer of unfractonated bone marrow cells, or stem cells, and progenitor cells derived from bone marrow can enhance functional recovery after acute MI.\textsuperscript{10}

Previous clinical investigations indicated that infusion of autologous bone marrow cells into the infarct-related coronary artery would be feasible after acute MI.\textsuperscript{19,20} Our randomized controlled clinical trial addressed the effects of autologous bone marrow cell therapy on LV function recovery after acute ST segment elevation MI. On average, 128 ml of bone marrow were aspirated from 10 patients that resulted in the recovery of around 24.6 million cells per infusion. Clinical follow-up of patients revealed that the method was safe and no side effects such as fever, acute thrombosis, reoccurrence of MI or proarrhythmia were observed.

Compared to control group, the LVEF in the bone marrow cell treated group increased significantly 6 months after the infusion of autologous bone marrow cells into the infarct-related coronary artery. However, the difference in LVEF between the two groups was not significant before the treatment. Thus, the difference observed might not have been caused by the stent but was rather a result of bone marrow treatment. Strauer et al. reported insignificant increments of LVEF in both groups.\textsuperscript{19} Lunde et al. showed that intracoronary injection of mononuclear stem cells caused an increase of 7.6 ± 10.4\% in mean LVEF (baseline value: 46.3 ± 9.5\%) in both groups. In contrast to our results, they did not observe a significant difference between the two groups.\textsuperscript{21} Schachinger et al. indicated that at four months follow-up, the absolute improvement in the global LVEF was significantly greater in the case (bone marrow cell) group than in 3.0 ± 6.5\%; P < 0.01). They stated that patients with a baseline LVEF at or below the median value of 48.9\% enjoyed the most benefits,\textsuperscript{22} which is in agreement with our results.

The enhanced LVEF in the treated group compared to the control group probably due to the bone marrow treatment emphasizes the need for additional therapeutic strategies to promote functional recovery in patients with acute MI. Serial LVEF measurements in patients with reperfused myocardium after acute MI have revealed no significant improvements in LVEF (from the baseline at the 5th-7th days to the follow-up at the 3rd-6th months).\textsuperscript{23,24} These results are consistent with insignificant improvements of LVEF in the control group. The LVEF improvement has been suggested to be a result of improved regional systolic wall motion in the infarct border zone and not due to the improved LV remodeling at the 6th month.\textsuperscript{25}

In contrast to our results, Strauer et al. found that compared to the standard therapy group, intracoronary injection of monoclonal stem cells decreased regional wall motion abnormality index in the cell therapy group after three months.\textsuperscript{19} This inconsistency could be related to the different patients selected by the two studies. Strauer et al. also reported insignificant LVEF increments in both groups since they studied MI patients with a mean LVEF of 57 ± 8\% but in our study the mean LVEF was around 30\%.\textsuperscript{19}

Therefore, patients in this study have substantial functional impairment.

The 19.2\% rise in LVEF in the treated group versus the 3.7\% increase in the control group emphasizes the need for additional therapeutic strategies to enhance functional recovery in patients with acute MI. The obtained increase was also higher than LVEF improvement (up to 4\%) that can be achieved when coronary potency is reestablished within 4 hours of symptoms onset.\textsuperscript{23}

The 19.2\% increase in this study is greater than LVEF improvements reported by other studies.\textsuperscript{25} This difference could be due to selection of patients with very low LVEF or due to the added growth factor to cells during the overnight culture.

Our results are consistent with the reports suggesting cell transfer to be more beneficial than established strategies to promote functional recovery after acute MI, such as percutaneous coronary interventions, PCI with stent implantation, and post infarction pharmacotherapy.\textsuperscript{14,26}

This study was not designed to assess the underlying mechanisms of treatment with bone marrow cells that promote functional recovery after acute MI. Apparently, trans differentiations of bone marrow derived hematopoietic stem cells to cardiac myocytes cannot account for their beneficial effects. Instead, recent papers have highlighted the potential of bone marrow cells to promote paracrine effects in
the ischemic tissues (e.g. secretion of angiogenic factors), and suggest that paracrine signaling, rather than cell incorporation, promotes functional recovery. It is also possible that adding bFGF, IGF-I and VEGF promoted the differentiation of CD 34+ cells in the medium to endothelial cell colonies and led to aforementioned improvements. The presence of VEGF has been reported to be critical for endothelial differentiation in vitro, even though bFGF and IGF-1 enhanced endothelial colony formation. Furthermore, the usage of colony-stimulating factor was avoided since high rates of in-stent restenosis have been reported after intracoronary transfer of granulocyte and mobilized peripheral blood mononuclear cells. This effect may be mediated by enhancing neutrophil recruitment at sites of tissue injury.

It is of interest to note that nucleated bone marrow cells are significantly smaller than expanded mesenchymal stromal cells ex vivo, which may explain why we and others did not observe infarctions after intracoronary transfer of bone marrow cells.

Finally, the results of our study indicated that intracoronary bone marrow stem cell transplantation is safe and feasible. Overall, the results are encouraging and support the idea that autologous bone marrow cells can be used to enhance LV functional recovery in patients after acute MI and decrease the incidence of heart failure.

Conflict of Interests
Authors have no conflict of interests.

References
1. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88(1): 107-15.
2. Arai AE, Pantely GA, Thoma WJ, Anselone CG, Bristow JD. Energy metabolism and contractile function after 15 beats of moderate myocardial ischemia. Circ Res 1992; 70(6): 1137-45.
3. Heyndrickx GR, Baig H, Nellens P, Leusen I, Fishbein MC, Vatner SF. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol 1978; 234(6): H653-H659.
4. Griggs DM, Tchokoev VV, Chen CC. Transmural differences in ventricular tissue substrate levels due to coronary constriction. Am J Physiol 1972; 222(3): 705-9.
5. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56(5): 786-94.
6. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74(5): 1124-36.
7. Pfeffer MA. Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995; 46: 455-66.
8. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34(3): 890-911.
9. Schwarz F, Schuler G, Katus H, Hofmann M, Manthey J, Tillmanns H, et al. Intracoronary thrombolysis in acute myocardial infarction: duration of ischemia as a major determinant of late results after recanalization. Am J Cardiol 1982; 50(5): 933-7.
10. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410(6829): 701-5.
11. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7(4): 430-6.
12. Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001; 37(6): 1726-32.
13. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98(18): 10344-9.
14. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104(24): 2996-3007.
15. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobson AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105(4): 539-42.
16. Keeley EC, Boura JA, Grines CL. Primary angioplasty
versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351): 13-20.

17. Giugliano RP, Braunwald E. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it’s all a matter of time. Circulation 2003; 108(23): 2828-30.

18. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35(3): 569-82.

19. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106(15): 1913-8.

20. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106(24): 3009-17.

21. Lund K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355(12): 1199-209.

22. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355(12): 1210-21.

23. Murry CE, Soonpaa MH, Reinecke H, Nakajima HO, Rubin M, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428(6983): 664-8.

24. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004; 94(5): 573-4.

25. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92(2): 362-7.

26. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100(9): 1016-30.

27. Chakraborty A, Hentzen ER, Seo SM, Smith CW. Granulocyte colony-stimulating factor promotes adhesion of neutrophils. Am J Physiol Cell Physiol 2003; 284(1): C103-C110.

28. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, Koo BK, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363(9411): 751-6.